Johnson & Johnson (JNJ) : Old Dominion Capital Management Inc added new position in Johnson & Johnson during the most recent quarter end. The investment management firm now holds 5,473 shares of Johnson & Johnson which is valued at $678,105 , the company said in a statement filed on Aug 2, 2016 with the SEC.Johnson & Johnson makes up approximately 0.79% of Old Dominion Capital Management Inc’s portfolio.
Other Hedge Funds, Including , Buckingham Asset Management reduced its stake in JNJ by selling 1,307 shares or 5.34% in the most recent quarter. The Hedge Fund company now holds 23,146 shares of JNJ which is valued at $2,867,789. Johnson & Johnson makes up approx 0.95% of Buckingham Asset Management’s portfolio.Wright Investors Service Inc reduced its stake in JNJ by selling 3,020 shares or 62.92% in the most recent quarter. The Hedge Fund company now holds 1,780 shares of JNJ which is valued at $220,542. Johnson & Johnson makes up approx 0.09% of Wright Investors Service Inc’s portfolio.Ken Stern Associates boosted its stake in JNJ in the latest quarter, The investment management firm added 408 additional shares and now holds a total of 10,428 shares of Johnson & Johnson which is valued at $1,303,813. Johnson & Johnson makes up approx 0.97% of Ken Stern Associates’s portfolio.Beacon Financial Group reduced its stake in JNJ by selling 1,491 shares or 1.54% in the most recent quarter. The Hedge Fund company now holds 95,157 shares of JNJ which is valued at $11,704,311. Johnson & Johnson makes up approx 2.46% of Beacon Financial Group’s portfolio.Campbell Newman Asset Management Inc boosted its stake in JNJ in the latest quarter, The investment management firm added 28,965 additional shares and now holds a total of 42,323 shares of Johnson & Johnson which is valued at $5,205,729. Johnson & Johnson makes up approx 0.92% of Campbell Newman Asset Management Inc’s portfolio.
Johnson & Johnson closed down -0.59 points or -0.47% at $123.65 with 52,32,469 shares getting traded on Monday. Post opening the session at $124, the shares hit an intraday low of $123.23 and an intraday high of $124.15 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
On the company’s financial health, Johnson & Johnson reported $1.74 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 19, 2016. Analyst had a consensus of $1.68. The company had revenue of $18482.00 million for the quarter, compared to analysts expectations of $17985.80 million. The company’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.71 EPS.
Many Wall Street Analysts have commented on Johnson & Johnson. Company shares were Reiterated by UBS on Jul 20, 2016 to “Buy”, Firm has raised the Price Target to $ 137 from a previous price target of $126 .Company shares were Reiterated by RBC Capital Mkts on Jul 20, 2016 to “Outperform”, Firm has raised the Price Target to $ 133 from a previous price target of $125 .Standpoint Research Initiated Johnson & Johnson on May 20, 2016 to “Sell”, Price Target of the shares are set at $94.
Johnson & Johnson is a holding company. The Company is engaged in the research and development manufacture and sale of a range of products in the health care field. The Company has more than 265 operating companies conducting business around the world. The Companys primary focus is products related to human health and well-being. The Company is organized into three business segments: Consumer Pharmaceutical and Medical Devices. The Company’s subsidiaries operate 134 manufacturing facilities occupying approximately 21.5 million square feet of floor space. The Companys research facilities are located in the United States Belgium Brazil Canada China France Germany India Israel Japan the Netherlands Singapore Switzerland and the United Kingdom.